InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (2 ops.)
Explore the detailed record of transactions filed by Booth Andrew, Chief Financial Officer. Officer active across 1 companies, notably AbCellera Biologics Inc.. In total, 9 filings have been published. Total volume traded: €52.1m. The latest transaction was filed on 12 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
€474,15285,000 shares@ €5.57830.038% mcap0.9% of flow
Common Shares
SEC:0001209191-22-029091:0·
Ideal exit: 6 Feb 2023 (T+270)
€141,677500,000 shares@ €0.28340.011% mcap0.5% of flow
Common Shares
SEC:0001209191-21-069084·
€141,677500,000 shares@ €0.28340.011% mcap0.3% of flow
Common Shares
SEC:0001209191-21-069084:0·
€686,57053,500 shares@ €12.83310.055% mcap2.6% of flow
Common Shares
SEC:0001209191-21-064378·
Ideal exit: 8 Aug 2022 (T+270)
€686,57053,500 shares@ €12.83310.055% mcap1.3% of flow
Common Shares
SEC:0001209191-21-064378:0·
Ideal exit: 8 Aug 2022 (T+270)
€25m1,200,000 shares@ €20.93252.01% mcap96.5% of flow
Common Shares
SEC:0000899243-21-022988·
€25m1,200,000 shares@ €20.93252.01% mcap47.8% of flow
Common Shares
SEC:0000899243-21-022988:0·
€93,491600,000 shares@ €0.15580.0075% mcap0.2% of flow
Common Shares
SEC:0000899243-21-022894:0·
€93,491600,000 shares@ €0.15580.0075% mcap0.4% of flow
Common Shares
SEC:0000899243-21-022894·
9 of 9 declarations
About Booth Andrew
Andrew Booth is the Chief Financial Officer of AbCellera Biologics Inc. In this role, he is responsible for the company's financial management, including financial planning, analysis, and strategy. His expertise in finance and resource management contributes to the growth and sustainability of the company. Andrew plays a key role in making strategic decisions that support AbCellera's long-term goals.
